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Abstract
Background: The aim of this study was to assess the psychometric properties of the EQ-5D-3 L, the SF-12 v2 and
its preference based derivative the SF-6D, and the St Georges Respiratory Questionnaire (SGRQ), in patients
diagnosed with Acute Respiratory Distress Syndrome (ARDS).
Methods: Data from the Oscillation in ARDS (OSCAR) randomised unblinded clinical trial of 795 patients
diagnosed with ARDS provided the foundation of this secondary psychometric analysis. The three source
patient reported outcome measures (PROMs) (EQ-5D-3 L, SF-12 and SGRQ) were collected at both 6 and
12 months post randomisation. All measures were tested for acceptability, reliability, internal consistency,
validity and responsiveness. Data from responders at 6 months was used to test for acceptability, reliability,
known groups validity and internal responsiveness. Data from patients who responded at both 6 and
12 months was used to test for convergent validity and external responsiveness.
Results: Rates of response at both 6 and 12 months post randomisation were 89.88 % for the EQ-5D-3 L,
77.38 % for the SF-6D, 71.43 % for both the physical and mental components of the SF-12 and 38.10 % for
the SGRQ. All measures had a Cronbach’s Alpha statistic higher than 0.7. For known group’s validity, there
was no difference in mean summary or utility scores between known groups for all PROMs with minimal
effect sizes. All three source measures showed strong convergent and discriminant validity. There was
consistent evidence that the SF-6D is an empirically valid and efficient alternative to the EQ-5D-3 L. The EQ-
5D-3 L and SGRQ were more responsive compared to the SF-12 and SF-6D with the EQ-5D-3 L generating
greater effect sizes than the SGRQ.
Conclusion: The PROMs explored in this study displayed varying psychometric properties in the context of
ARDS. Further research should focus on shortening the SGRQ whilst still maintaining its psychometric
properties and mapping between the SGRQ and preference-based measures for future application within
economic evaluations of respiratory focused interventions. The selection ofa preferred PROM for evaluative
studies within the ARDS context should ultimately depend on the relative importance placed on individual
psychometric properties and the importance placed on generation of health utilities for economic evaluation
purposes.
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Background
Acute Respiratory Distress Syndrome (ARDS) is a severe
life threatening condition, which develops if the lungs
become severely inflamed due to an infection or injury.
Although there is a low incidence (approximately 78–
280 cases per million population), ARDS is associated
with a high mortality rate of 40 % or greater [1–9]. It
is estimated that due to long intensive care unit and
hospital stays, the cost of every saved life from ARDS
is approximately £43,000 (2010 prices) [10, 11]. Pa-
tients who survive ARDS tend to have a high number
of comorbidities and a poor health-related quality of
life (HRQoL) with 35 % unable to return to work
24 months after hospital discharge [12, 13]. Health
care costs tend to increase after surviving ARDS due
to the need for hospital readmission and inpatient re-
habilitation [14].
Patient reported outcomes (PROs) such as symptoms
and health utilities can be measured through self-
reported questionnaires of health status or HRQoL,
which are completed by patients at different time points
and are otherwise known as patient reported outcome
measures (PROMs). PROMS can be used to compare
patients’ self-reported health status or HRQoL at two
separate points in time, allowing analyses of the change
in health status or HRQoL with respect to an interven-
tion [15, 16]. The inclusion or use of poorly designed or
inadequately targeted PROMs in a study that has not
considered their psychometric properties can have ad-
verse consequences. These include an additional burden
to the patient, an increase in study costs and ethical con-
cerns surrounding patients having to complete measures
that are incapable of capturing the patient’s perspective
[17]. This could also lead to missing data, unreliable in-
formation and biased results. These consequences
should therefore be avoided with further research and
evidence of the psychometric properties of PROMs in
particular populations.
The OSCAR (Oscillation in ARDS) study was con-
ducted to assess the effectiveness and cost-effectiveness
of High Frequency Oscillatory Ventilation (HFOV)
against conventional artificial ventilation for adults
with ARDS. The OSCAR study included the EQ-5D-
3 L, SF-12 and the St Georges Respiratory Question-
naire (SGQ) in patients diagnosed with moderate to
severe ARDS.
There is limited evidence regarding the psychomet-
ric properties of PROMs used in critical care and no
evidence in patients with ARDS [18–21]. Menn et al
[18] found that in patients with severe Chronic
Obstructive Pulmonary Disorder (COPD) hospitalised
for exacerbations, the EQ-5D-3 L appeared to be a
suitable measure of HRQoL, whereas the SF-12 ap-
peared to be less suitable for a self-assessment due to
the high proportion of missing values. Additionally,
the psychometric properties of the SGRQ were satis-
factory in this population group, although there was a
recognition that no utility values (preference based
outcomes) could be derived using this PROM [18].
Therefore, considering that there has been limited
information on the properties of alternative PROMS
in critical care, and no previous assessments in the
context of ARDS, the objective of this study was to
assess the psychometric properties of the EQ-5D-
3 L, the SF-12 and its preference based derivative
the SF-6D, and the SGRQ, in patients diagnosed with
ARDS.
Methods
Study population
The data used in this study was derived from the OSCAR
trial, which was a randomised unblinded controlled trial
with a prospective cost utility analysis [22, 23]. Further de-
tails regarding the OSCAR trial are available in the pub-
lished literature [22–24].
Patients did not complete any PROMs at baseline as
they were intubated at that stage. Patients were followed
up at 6 and 12 months after randomisation using self-
complete postal questionnaires, which contained the
EQ-5D, SF-12 v2 (hereafter SF-12 for brevity) and the
SGRQ [24].
Patient reported outcome measures
The EQ-5D-3 L is a generic preference based question-
naire, which asks patients about their health status on the
day they complete the questionnaire. The EQ-5D-3 L has
five separate dimensions: mobility, self care, usual activ-
ities, pain/discomfort and anxiety/depression. Each of
these dimensions has three response levels (no problems,
some or moderate problems and severe or extreme
problems) [25, 26]. Therefore, there are a possible
243 (35) health states that can be generated from the
EQ-5D-3 L descriptive system. The EQ-5D is gener-
ally valued using a time-trade method. For the pur-
poses of this study, we applied the York A1 (Dolan)
tariff set derived from a survey of the UK general
population (n = 3337), which used the time trade-off
valuation method to estimate utility scores for a sub-
set of 45 EQ-5D health states, with the remainder of
the EQ-5D health states subsequently valued through
the estimation of a multivariate model [27]. Resulting
utility scores range from -0.59 to 1.0, with 0 repre-
senting death and 1.0 representing full health; values
below 0 indicate health states worse than death. The
EQ-5D-3 L visual analogue scale (VAS) was not used
within the OSCAR trial.
The SF-12 is a generic non-preference based PROM
which contains 12 questions selected from a parent
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PROM called the SF-36. The SF-12’s questions are
designed to provide patients or individuals with the
opportunity to recall their health status retrospect-
ively over a 4 week period. This questionnaire has
eight separate dimensions [28, 29]. The SF-12 mea-
sures various aspects of physical and mental health
from which physical (PCS) and mental (MCS) com-
ponent scores can be calculated [25]. Whilst such
scores provide a method for analysing the effective-
ness of interventions, they have only a limited appli-
cation in economic evaluations because they are not
based on population preferences. Hence a six dimen-
sion health state classification can also be con-
structed from the SF-12 called the SF-6D. The SF-6D
is a preference based measure that can generate
18,000 health states which can be converted into
utility values (ranging from 0.345 to 1.0) using a set
of preference weights obtained from the UK general
population and valued using the standard gamble
valuation technique [30].
The St Georges Respiratory Questionnaire (SGRQ) is a
50 item condition specific non-preference based PROM
developed to measure health status in patients with dis-
eases of airways obstruction. Three component scores
for the dimensions of symptoms, activity and impact on
daily life can be calculated and a total score can also be
calculated from the SGRQ. The symptoms component
score is concerned with the effects of respiratory symp-
toms, their frequency and severity. The activity compo-
nent scores is concerned with activities that cause or are
limited by breathlessness. The impact score is concerned
with social functioning and psychological disturbances
resulting from airways disease. The total score summa-
rises the impact of the disease on overall health status.
Scores can range from 0–100 with a higher score repre-
senting a lower respiratory health [31].
Statistical analysis
Baseline characteristics and descriptive characteristics
were computed. The difference between scores, char-
acteristics and utility values were tested using the un-
paired t-test for continuous variables and chi-squared
test for categorical variables and presented within ta-
bles. Missing data was excluded from all statistical
analyses. As there were no significant effects from the
trial intervention, patients within the OSCAR trial
were pooled for these secondary analyses regardless of
trial allocation [24]. Data from responders at 6 months
was used to test for acceptability, reliability, known
groups validity and internal responsiveness. Data from
patients who responded at both 6 and 12 months was
used to test for convergent validity and external
responsiveness.
The psychometric properties of each study PROM,
including its acceptability, internal consistency, reli-
ability, validity and responsiveness was assessed. This
was based on the COSMIN taxonomy [32] and a pre-
viously published checklist of assessment criteria for
PROMs [33].
Acceptability
The acceptability of the different study PROMs was
measured using completion rates of the different instru-
ments at 6 months post randomisation [25, 34].
Reliability
Internal consistency, which is a measure of reliability,
assesses whether several items that propose to meas-
ure the same general dimensions produce similar re-
sults. The internal consistency of each PROM was
measured by calculating its Cronbach’s alpha statistic.
A commonly accepted categorisation for internal
consistency has been to consider scores between 0.7
and 0.8 to be acceptable, 0.8 and 0.9 to represent good
reliability and 0.9 and higher to represent excellent re-
liability [33].
Construct validity
There are three common approaches to measuring con-
struct validity: known groups, convergent and discrim-
inant. Known groups’ comparisons were conducted
using groups categorised by the following baseline indi-
cators: PaO2/FiO2 ratio [35] and APACHE II [36]
scores. Using the 2012 “Berlin criteria” produced by the
European Society of Intensive Care Medicine, OSCAR
patients were classified into moderate or severe ARDS
based on their decreased PaO2/FiO2 ratio. If the ratio
was less than 13.3kPa then the patient was classified
as a severe ARDS patient and if it was greater than
13.3kPa then the patient was classified as a moderate
ARDS patient [22, 23, 35, 37]. Within the OSCAR
study, the APACHE II score was used to compute the
risk of dying and thus the severity of illness. An
APACHE II score higher than 26 indicated a less than
50 % chance of survival and an APACHE II score
lower than or equal to 26 indicated a more than
50 % chance of survival [22].
This analysis was conducted using independent t-tests
for differences at 6 months for all study PROMs. The
magnitude of the difference was estimated by calculating
the Cohen’s D effect size. A standard classification of
Cohen’s D effect sizes regards a value of 0.20 as a small
response, 0.50 as a moderate response and 0.80 or
greater as a large response [38].
Convergent and discriminant validity is the extent to
which PROMs with overlapping dimensions and con-
structs may be similar or different. It is expected that
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similar constructs between PROMs (e.g. pain in the EQ-
5D-3 L and pain in the SF-12) should correlate [25]. The
Pearson’s R correlation coefficients were calculated be-
tween summary scores and utility values to test for con-
vergent and discriminant validity. Dimensions and
domains were then correlated amongst the EQ-5D-3 L,
SF-12, SF-6D and SGRQ. Spearman ranks correlation
was used to assess whether there was a relationship for
all dimensions to ascertain convergent or discriminant
validity with the assumption that similar dimensions in
different measures should correlate more than different
dimensions within the same measure. A higher correl-
ation between a generic source PROM and the SGRQ
can be considered as evidence of a greater degree of
construct overlap between the generic measure and the
SGRQ [25].
Empirical validity
Empirical validity has been defined as whether a
preference-based measure generates utility scores that
reflect people’s preferences whether revealed stated or
hypothesised [39]. Empirical validity was tested using
the relative efficiency (RE) statistic to detect differ-
ences in an external measure of health status. This
test was only conducted on the EQ-5D-3 L and the
SF-6D (our two preference-based measures). This test
could not be conducted on the SGRQ as it is a con-
dition specific PROM that is not preference based.
Additionally, this test was distinguished from the
other tests of validity that are applied to all the
PROMs. In order to calculate the RE statistic, all re-
sponders at 6 months were dichotomised using an ex-
ternal measure of current general health (derived
from Question 1 of the SGRQ) and current respira-
tory health (derived from the SGRQ Total Score).
Current general health was dichotomised as very good
or good versus fair, poor or very poor [39]. The
dichotomisation for current reported respiratory
health was an SGRQ total score of less than or equal
to 40 (considered to be very good or good respiratory
health) versus an SGRQ total score of more than 40
(considered to be fair, poor or very poor respiratory
health). Previous research into the validity of the
SGRQ in COPD patients used a threshold of 33 for
the SGRQ total score to identify COPD; however,
considering the severity of ARDS, the authors felt
that a threshold of 33 would be too low to dichotom-
ise an ARDS population [21, 40].
Responsiveness
Responsiveness was categorised into internal and ex-
ternal responsiveness. Responsiveness can be assessed
by examining floor and ceiling effects of the measure
to determine the extent to which a person can move
on the scale if their HRQoL changes over time [41].
Further testing to determine internal and external
responsiveness could not be conducted between base-
line and follow up periods. We did however test for
external responsiveness of the EQ-5D-3 L, SF-12, SF-
6D and SGRQ between 6 and 12 months. Here an
external reference measure was provided by the SF-12
Question 1, which asked about current general health
with possible responses of very good, good, fair, poor
or very poor at both 6 and 12 months used to cat-
egorise participants. This reference measure was
chosen as it was not used in the calculation of any
utility or summary scores. This objective was to test
whether the changes registered by a measure over
time resemble those expected based on an external
measure of health [25, 42]. Mean differences calcu-
lated by paired t-tests and standardised response
means were calculated to ascertain changes in the
outcome measures for patients in the self-reported
(current general health) groups. A larger difference
between groups indicated a more responsiveness
measure [25].
Results
A total of 795 patients were randomised within the
OSCAR study of whom 168 were complete study re-
sponders, meaning all three source PROMs (EQ-5D-
3 L, SF-12 & SGRQ) were completed and returned at
both 6 months and 12 months post randomisation.
The baseline characteristics of the study population
are shown in Table 1. There was no difference be-
tween patients who responded at both 6 and
12 months, incomplete responders and patients who
did not complete any questionnaires at either 6 or
12 months follow up in terms of sex or ARDS type.
However, there was a significant difference in average
age between all three groups (P < 0.001). Incomplete
responders tended to be younger than both patients
who responded to questionnaires at both follow up
points and also patients who did not complete any
questionnaires at either follow up point (P < 0.05).
There was also a difference in average weight between
patients who responded at both follow ups and pa-
tients who did not complete any questionnaires at ei-
ther follow up point (P < 0.001).
Descriptive statistics
Descriptive statistics were calculated for each out-
come measure and are shown in Table 2. Here the
EQ-5D-3 L produced lower utility values compared to
the SF-6D at 6 months post randomisation. Table 2
also summarizes levels of floor and ceiling effects for
all PROMs. The EQ-5D-3 L showed evidence of ceil-
ing effects. There was no evidence of a floor or
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ceiling effect for the SF-6D or the SF-12. A ceiling ef-
fect was seen for all the summary scores of the
SGRQ and a floor effect for the SGRQ activity score.
Acceptability
Table 2 also shows the response rates for each PROM
at 6 month follow up post randomisation. Response
rates varied between 95.29 and 74.79 % at 6 months.
The EQ-5D-3 L had a very high response rate, whilst
the SF-6D had response rates that were marginally
greater than the SF-12 components (PCS and MCS
scores). The SGRQ had a wide range of response
rates with the symptoms score generating the greatest
response compared to the activity, impact and total
scores. The SGRQ total score was also found to have
had the lowest response rate.
Reliability
All three source PROMs generated Cronbachs alpha sta-
tistics greater than 0.7, which was deemed acceptable for
research purposes [43]. Cronbach's alpha scores were
found to be 0.732, 0.880 and 0.963 for the EQ-5D-3 L,
SF-12 and the SGRQ respectively.
Validity
Construct validity
The results for the tests of known groups’ validity are
summarized in Tables 3 and 4. The known group validity
test had to be conducted at 6 months due to the absence
of baseline values at randomisation. The difference in
the scores for all measures specified by baseline APA-
CHE II scores and PaO2/FiO2 ratios indicated that there
Table 2 Descriptive statistics for each patient reported outcome measure used in the 6 month follow up post randomisation in the
OSCAR trial
Range N Mean SD Response rates Floor effects Ceiling effects
EQ-5D-3 L (Utility) −0.594 to 1 234 0.60 0.36 95.29 % 0.00 % 19.73 %
SF-6D (Utility) 0.345 to 1 218 0.66 0.16 93.16 % 0.92 % 0.92 %
SF-12 PCS 0 to 100 209 36.88 12.32 89.32 % 0.00 % 0.00 %
SF-12 MCS 0 to 100 209 43.43 13.30 89.32 % 0.00 % 0.00 %
SGRQ Symptoms Score 0 to 100 221 33.71 27.89 94.44 % 1.36 % 1.36 %
SGRQ Activity Score 0 to 100 193 46.04 31.80 82.47 % 7.77 % 7.77 %
SGRQ Impact Score 0 to 100 194 22.13 22.42 82.90 % 0.00 % 0.00 %
SGRQ Total Score 0 to 100 175 32.08 24.18 74.79 % 0.00 % 0.00 %
Scores or Utility Values of participants which could not be calculated due to missing items were not included within the analysis
N stands for the sample size. SD denotes the standard deviation. CI is abbreviated for confidence intervals
Floor effects is the proportion of patients in the lowest health state possible and ceiling effects is the proportion of patients in the highest health state poss
EQ-5D-3 L is anchored at -0.594 for worst possible health and 1 for best possible health
SF-6D is anchored at 0.345 for worst possible health and 1 for best possible health
SF-12 PCS & MCS scores are anchored at 0 for worst possible health and 1 for best possible health
SGRQ scores are anchored at 100 for worst possible health and 0 for best possible health
The EQ-5D-3 L and SF-12 was assessed in terms of complete responses for all questions
The SF-6D was regarded complete if there was sufficient items to calculate a score
The SGRQ was assessed by calculating if more than 24 % of the items were missing or not answered, then a total score could not be calculated
Table 1 Baseline characteristics of the OSCAR study population
Whole population
(n = 795)
Responders at both 6 and 12 months
(n = 168)
Incomplete responders
(n = 101)
Patients without any PROMs data
(n = 526)
Mean Age (SD) 54.90 (16.76) 54.82 (15.10) 47.39 (16.08) 56.37 (17.03)
Mean Weight (SD) 79.7 (21.35) 83.18 (19.49) 80.05 (25.76) 78.53 (20.90)
Male (%) 495 (62.3 %) 114 (67.9 %) 62 (61.4 %) 319 (60.6 %)
Female (%) 300 (37.7 %) 54 (32.1 %) 39 (38.6 %) 207 (39.4 %)
Moderate ARDS (%) 478 (59.9 %) 107 (63.7 %) 61 (60.4 %) 308 (58.6 %)
Severe ARDS (%) 319 (40.1 %) 61 (36.3 %) 40 (39.6 %) 218 (41.4 %)
SD denotes standard deviation. “Patients without any PROMs data” includes patients who died before follow up and survivors who didn’t respond to either follow
up questionnaire
The unit for age was in years. The unit for weight was in kilograms. Male, Female, Moderate & Severe ARDS are shown as absolute numbers with the proportion
of each gender or ARDS type shown in brackets
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was no difference between the known groups for all
PROMs with minimal effect sizes.
Convergent and discriminant validity
Table 5 shows Pearsons R correlation coefficients be-
tween various summary and outcome measures. The
majority of summary and outcome measures corre-
lated however, the PCS and MCS of the SF-12 did
not significantly correlate. The EQ-5D-3 L utility
scores correlated more strongly with the SF-6D utility
score. The EQ-5D-3 L utility scores also correlated
moderately with the SF-12 PCS component score
[44]. There was a strong correlation between compo-
nent SGRQ scores (symptom, activity, impact and
total) at the statistically significant 5 % level. Lastly,
there was weak correlation between SGRQ scores and
the EQ-5D-3 L, SF-6D and both SF-12 components
(PCS and MCS) [44].
Spearman Rank correlation was used to assess
whether there was a relationship between dimensions
to ascertain convergent or discriminant validity. Here,
similar dimensions (in terms of underlying health
construct) correlated whilst unrelated dimensions did
not correlate (See Appendix A). For example, the pain
dimension in the EQ-5D-3 L and the bodily pain sub-
domain within the SF-12 correlated strongly. Add-
itionally, the anxiety dimension in the EQ-5D-3 L and
the mental health sub-domain in the SF-12 also cor-
related strongly. The EQ-5D-3 L self care dimension
and the SGRQ symptom score did not correlate.
Additionally, both the EQ-5D-3 L dimensions for
self-care and usual activity did not correlate with ei-
ther EQ-5D-3 L dimension for anxiety/depression or
the SF-12 dimension of mental health. The EQ-5D-
3 L dimension for self-care did not correlate with
the SGRQ symptom score either. Lastly, there was
no correlation between the role functioning (phys-
ical) sub-domain and the mental health sub-domain
in the SF-12.
Empirical validity
Empirical validity was tested using RE statistics for
dichotomised self-reported current general health sta-
tus and current respiratory health. Tables 6 and 7
shows that that the SF-6D was found to be approxi-
mately 56-57 % more efficient than the EQ-5D-3 L at
Table 3 Known groups validity – APACHE II scores
APACHE score
< =26 mean (SD)
APACHE score
< =26 n
APACHE score
>26 Mean (SD)
APACHE score
>26 n
Difference P value Confidence intervals Cohen’s D
EQ-5D-3 L (Utility) 0.61 (0.35) 195 0.47 (0.40) 28 0.14 0.058 −0.05 0.28 0.38
SF-6D (Utility) 0.64 (0.15) 191 0.62 (0.16) 27 0.05 0.155 −0.02 0.12 0.29
SF-12 PCS 36.90 (12.45) 185 36.70 (11.51) 24 0.20 0.942 −5.09 5.48 0.02
SF-12 MCS 45.99 (13.24) 185 41.12 (13.21) 24 4.87 0.001 −0.79 10.55 0.37
SGRQ Symptoms Score 33.04 (28.00) 194 38.57 (27.05) 27 −5.54 0.334 −16.83 5.75 0.20
SGRQ Activity Score 45.91 (31.26) 169 48.63 (36.07) 24 2.72 0.696 −16.44 10.99 0.09
SGRQ Impact Score 22.08 (22.46) 169 22.49 (22.65) 25 0.41 0.932 −9.91 9.09 0.02
SGRQ Total Score 31.95 (23.97) 154 33.04 (26.29) 21 1.09 0.847 −12.22 10.05 0.04
SD denotes standard deviation
Table 4 Known groups validity – PaO2/FiO2 ratio
Moderate ARDS
mean (SD)
Moderate
ARDS n
Severe ARDS
mean (SD)
Severe
ARDS n
Difference P value Confidence
interval
Cohen’s D
EQ-5D-3 L (Utility) 0.60 (0.39) 141 0.58 (0.31) 82 0.02 0.749 −0.08 0.16 0.04
SF-6D (Utility) 0.66 (0.16) 138 0.65 (0.14) 80 0.01 0.586 −0.03 0.06 0.08
SF-12 PCS 37.60 (12.49) 131 35.66 (12.02) 78 1.93 0.274 −1.54 5.41 0.16
SF-12 MCS 46.04 (12.80) 131 44.41 (14.12) 78 1.64 0.391 −2.11 5.39 0.12
SGRQ Symptoms Score 31.73 (27.31) 140 37.15 (28.72) 81 −5.42 0.164 −13.08 2.24 −0.19
SGRQ Activity Score 43.59 (31.69) 120 50.62 (31.71) 73 −7.03 0.137 −16.31 2.25 −0.22
SGRQ Impact Score 20.57 (22.14) 120 24.65 (22.80) 74 −4.08 0.219 −10.61 2.44 −0.18
SGRQ Total Score 37.14 (28.72) 108 35.18 (23.98) 67 −5.03 0.182 −12.44 2.38 −0.21
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detecting differences in these external measures of
health status.
Responsiveness
Table 8 shows the external responsiveness results using
self-reported change in current general health as the ref-
erent. The change in EQ-5D-3 L utility score ranged
from a change of 0.13 for patients who felt that their
health was much better to a change of -0.18 for patients
who felt that their health was much worse. This mir-
rored the pattern for the SF-6D where the change in SF-
6D utility score ranged from a change of 0.03 for pa-
tients who felt that their health was much better to a
change of -0.09 for patients who felt that their health
was much worse.
The SF-6D responsiveness results did have an ex-
ception where the change in summary scores between
the much better (0.03) and better (0.05) self-reported
general health categories were in reverse order to that
which was expected. The SF-12 PCS summary score
ranged from a change of 14.80 for patients who felt
that their general health was much better to a change
of -12.38 for patients who felt that their general
health was much worse. The SF-12 MCS summary
score showed much more inconsistency in responsive-
ness. For patients who felt that their general health
was much better, the SF-12 MCS summary score
produced a change of -0.42 which indicated that
mental health had decreased over time. A similar
phenomenon was also seen for the self-reported cat-
egory of “much worse” general health, where patients
who felt much worse produced a change in the SF-12
MCS summary score of 4.28 indicating that although
patients felt much worse, mental health had im-
proved. Finally the SGRQ total score (0–100 with a
higher score representing a lower respiratory health)
ranged from a change of -6.9050 for patients who felt
that their health was much better to a change of
35.1100 for patients who felt that their health had de-
teriorated. The SGRQ responsiveness followed the
general trend that was estimated. Effect sizes were
consistently ordered among the EQ-5D-3 L and
SGRQ with the EQ-5D-3 L generating larger effect
sizes compared to the SGRQ. Effect sizes for the SF-
12 and its SF-6D derivative were smaller.
Discussion
The aim of this study was to compare and assess the
psychometric properties of the EQ-5D-3 L, SF-12 and its
preference based derivative the SF-6D, and the SGRQ, in
patients with moderate to severe ARDS. This study
aimed to provide evidence for the use of generic and
condition specific PROMs in future clinical trials and
trial based economic evaluations associated with critical
Table 5 Convergent & discriminant validity - Pearson’s R correlation
EQ-5D-3 L
(Utility)
SF-6D
(Utility)
SF-12 PCS
(Utility)
SF-12 MCS
(Utility)
SGRQ Symptoms
score (Utility)
SGRQ Activity
score (Utility)
SGRQ Impact
score (Utility)
SGRQ Total
score (Utility)
EQ-5D-3 L (Utility) 1.00
SF-6D (Utility) 0.77 1.00
SF-12 PCS 0.60 0.62 1.00
SF-12 MCS 0.49 0.67 −0.07 1.00
SGRQ Symptoms Score −0.35 −0.43 −0.30 −0.39 1.00
SGRQ Activity Score −0.38 −0.44 −0.46 −0.19 0.58 1.00
SGRQ Impact Score −0.47 −0.52 −0.43 −0.35 0.71 0.77 1.00
SGRQ Total Score −0.45 −0.52 −0.46 −0.31 0.78 0.91 0.95 1.00
Correlation Coefficients in bold were not significant at 95 % confidence
Table 6 Empirical validity at 6 months using self-reported general health
Measure at 6 months Categorisation of self-reported current health N Mean SD t-statistic p-value Relative efficiency
EQ-5D-3 L Very Good or Good 68 0.79 0.23 6.13 P < 0.001 1.57
Fair, Poor or Very Poor 87 0.50 0.34
SF-6D Very Good or Good 67 0.76 0.14 7.69 P < 0.001
Fair, Poor or Very Poor 88 0.60 0.12
N is the sample size. SD denotes the standard deviation. Relative efficiency statistic is referenced at 1.0 for the EQ-5D-3 L. A relative efficiency value higher than
1.0 shows that the SF-6D is more efficient than the EQ-5D-3 L
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Table 7 Empirical validity at 6 months using self-reported respiratory health
Measure at 6 months Categorisation of self-reported respiratory health. N Mean SD t-statistic p-value Relative efficiency
EQ-5D-3 L Q1 or Q2 90 0.69 0.31 4.14 P < 0.001 1.56
Q3, Q4 or Q5 33 0.43 0.30
SF-6D Q1 or Q2 90 0.70 0.13 5.18 P < 0.001
Q3, Q4 or Q5 32 0.56 0.10
N is the sample size. SD denotes the standard deviation. Relative efficiency statistic is referenced at 1.0 for the EQ-5D-3 L. A relative efficiency value higher than
1.0 shows that the SF-6D is more efficient than the EQ-5D-3 L
Table 8 External responsiveness of all PROMs
EQ-5D-3 L N 6 months 12 months P value Difference SRM SRM CI Cohen’s D
Much Better 6 0.75 0.88 0.009 0.13 4.09 4.07 4.12 0.85
Better 33 0.67 0.75 0.028 0.08 2.30 2.28 2.31 0.31
Same 79 0.65 0.63 0.448 −0.02 −0.76 −0.77 −0.76 0.06
Worse 31 0.55 0.54 0.686 −0.02 −0.41 −0.42 −0.39 0.05
Much Worse 2 0.69 0.51 0.500 −0.18 −1.00 −1.25 −0.75 0.31
SF-6D N 6 Months 12 Months P Value Difference SRM SRM CI Cohen’s D
Much Better 6 0.71 0.74 0.592 0.03 0.57 0.53 0.62 0.21
Better 37 0.69 0.73 0.014 0.05 2.58 2.58 2.59 0.32
Same 74 0.67 0.69 0.045 0.02 2.04 2.05 2.05 0.15
Worse 28 0.66 0.67 0.814 0.00 0.23 0.23 0.25 0.04
Much Worse 2 0.69 0.60 0.205 −0.09 −3.00 −3.04 −2.96 0.41
SF-12 PCS N 6 Months 12 Months P Value Difference SRM SRM CI Cohen’s D
Much Better 6 35.60 50.40 0.004 14.80 4.95 2.56 7.34 1.36
Better 36 35.07 41.65 0.000 6.58 4.79 4.34 5.24 0.52
Same 71 38.32 40.63 0.002 2.13 2.87 2.70 3.05 0.19
Worse 26 37.45 35.15 0.1517 −2.30 −1.48 −2.08 −0.88 0.18
Much Worse 2 44.01 31.63 0.366 −12.38 −1.54 −12.66 9.57 1.37
SF-12 MCS N 6 Months 12 Months P Value Difference SRM SRM CI Cohen’s D
Much Better 6 49.81 49.39 0.897 −0.42 −0.14 −2.59 2.32 0.03
Better 36 48.15 50.21 0.222 2.06 1.24 −0.70 1.79 0.16
Same 71 44.53 45.24 0.502 0.72 0.68 0.43 0.92 0.05
Worse 26 49.29 46.76 0.226 −2.53 −1.24 −2.02 −0.46 0.20
Much Worse 2 40.00 44.28 0.707 4.28 0.50 −11.46 12.45 0.17
SGRQ Total Score N 6 Months 12 Months P Value Difference SRM SRM CI Cohen’s D
Much Better 4 20.54 13.64 0.012 −6.91 −5.10 −3.77 −6.43 0.54
Better 24 26.50 24.14 0.279 −2.37 −1.11 −0.26 −1.96 0.11
Same 50 30.00 30.53 0.789 0.53 0.27 0.82 −0.28 0.02
Worse 18 36.84 38.14 0.540 2.30 0.63 2.32 −1.07 0.09
Much Worse 1 19.37 54.48 N/A 35.11 N/A N/A N/A N/A
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care and specifically ARDS. The results of the study
showed significant variation between properties. Re-
sponse rates were varied with the EQ-5D generating the
highest response rates and the SGRQ generating the
lowest response rates. Cronbach’s alpha scores showed
that all PROMs were deemed acceptable to the study
population. Results also showed that there was no statis-
tically significant difference between known groups with
minimal effect sizes. All utility and summary scores cor-
related statistically with the exception of the SF-12 PCS
and MCS scores which did not correlate. When asses-
sing the empirical validity of the EQ-5D-3 L compared
to the SF-6D, results showed that the SF-6D was an effi-
cient and empirically valid alternative to the EQ-5D-3 L.
Lastly, the EQ-5D-3 L and SGRQ were more responsive
compared to the SF-12 and SF-6D with the EQ-5D-3 L
generating greater effect sizes than the SGRQ.
When comparing and assessing the psychometric
properties of PROMs, there are specific difficulties that
need to be addressed to provide transparency of the ana-
lysis. For instance, HRQoL can be measured in different
ways: the EQ-5D-3 L and SF-12 are generic PROMs and
measure general health whereas the SGRQ is a condition
specific PROM that measures HRQoL in relation to re-
spiratory concerns. Each of these PROMs also measures
HRQoL over different time periods: the EQ-5D-3 L asks
individuals about their health state “today,” whilst the
SF-12 and the SGRQ measures utilised in the OSCAR
study ask individuals about their health during or over
the past 4 weeks.
High response rates were seen for all measures due,
in part, to the strategy adopted to maximise patient
responses. A letter was sent out to survivors 2 weeks
before the follow up questionnaires were due at 6
and 12 months, as a reminder to the patient that they
would be receiving a questionnaire related to their
health from the trial group in the next few weeks.
When the follow up questionnaire was sent to pa-
tients, a freepost envelope was also sent to maximise
response rates. The PROMs within the follow up
questionnaires were ordered as follows: the SGRQ,
the EQ-5D-3 L and then the SF-12. This may partly
explain our response rates where the highest response
rate was observed for the SGRQ symptom score.
Hence, a large symptom score response rate may be
due to the patient having to first answer the first part
of the SGRQ (Questions 1–8), which results in a
symptom score. The second part of the SGRQ (Ques-
tions 9–16) results in activity and impact scores
which had lower response rates. Therefore, due to the
volume of the SGRQ (50 items), participant fatigue
and potential repeatability of dimensions relating to
respiratory health may have led to lower response
rates for the latter half of the SGRQ.
The EQ-5D-3 L was found to have an acceptable reli-
ability and internal consistency. The SF-6D and SF-12
showed greater reliability and internal consistency than
the EQ-5D-3 L. The SGRQ had high Cronbach’s alpha
statistics that exceeded 0.95. Scores higher than 0.95 are
not necessarily desirable, as this indicates that the items
may be entirely redundant [45]. Hence, there is a possi-
bility of item reduction or creating a derivative within
the SGRQ that could potentially aid in increasing re-
sponse rates, although this has to be counter-balanced
against the broader goals of the measure.
Construct validity was tested using known group’s
comparisons. With no outcomes measures being col-
lected at baseline, the known groups comparison was
a partial analysis to ascertain construct validity. For
the known groups based on APACHE II scores and
the PaO2/FiO2 ratio, it was found that there was no
difference between known groups and all effect sizes
were small. This highlights the need for research to
be conducted on measuring and valuing health for
the unconscious health state in ARDS patients so that
baseline assessments can also be conducted.
There was no correlation between SF-12 PCS and
MCS scores which would be expected as they are delin-
eated across different dimensions, which should provide
divergent constructs that are not overlapping. There was
strong correlation between the EQ-5D-3 L and the SF-
6D. All four SGRQ summary scores correlated highly
with each other, further highlighting the overlap between
its dimensions and constructs. This could be due to the
SGRQ being a condition specific measure but also due
to the greater amount of items used within the SGRQ.
The majority of Spearman Rank correlations were statis-
tically significant at the 95 % confidence level, which
shows that there was overlapping constructs between
measures. There was particularly strong correlation be-
tween the pain dimension in the EQ-5D-3 L and bodily
pain sub domain in the SF-12. There was also a strong
correlation between the anxiety dimension in the EQ-
5D-3 L and the mental health sub-domain in the SF-12.
Hence, both results provide evidence for convergent val-
idity. Furthermore, EQ-5D self care and EQ-5D usual ac-
tivities did not correlate with the anxiety/depression
dimension of the EQ-5D-3 L or the mental health sub-
domain of the SF-12 which shows some evidence for
discriminant validity between dimensions or domains.
All in all, correlation at both the utility/summary score
level and dimension specific level generated values
which revealed expected overlapping and non-
overlapping constructs. Hence, the PROMs displayed
convergent and discriminant validity.
Empirical validity was tested using relative efficiency
statistics to see whether the EQ-5D-3 L and SF-6D
generated utility or summary scores that reflected
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hypothesised differences in external indicators of health
status for current general health and total respiratory
health. For both the external indicators of current gen-
eral health and total respiratory health, the SF-6D was
found to be more efficient than the EQ-5D and
therefore considered to be an empirically valid alter-
native multi attribute utility measure to the EQ-5D.
This shows that the SF-6D is capable of discriminat-
ing between external indicators of health status in
keeping with the results of other studies [39].
As no baseline outcome measures were collected, it
was difficult to comprehensively test internal responsive-
ness and external responsiveness and hence basic floor
and ceiling effects were used to assess responsiveness.
The EQ-5D-3 L generated ceiling effects where respon-
dents chose the highest response on ordinal scales that
cannot be improved. In order to address this issue, the
EQ-5D-5 L has been created where there are five re-
sponse levels within each dimension, which should de-
crease ceiling effects [46]. The SF-12 and SF-6D had an
advantage in responsiveness due to lack of or absence of
floor or ceiling effects. The SGRQ had large ceiling ef-
fects, which shows that it has a limitation in its ability to
register health changes.
External responsiveness was also analysed where a
reference measure, Question 1 of the SF-12 that fo-
cuses on current general health, was used to assess
whether the changes registered by a measure over
time resemble those expected based on an external
measure of health. This reference measure was
chosen as it is not used in the calculation of any util-
ity or summary scores. We found that the EQ-5D-3 L
and SGRQ were more responsive than the SF-12 and
SF-6D. As a small sample has been analysed not all
mean comparisons are statistically significant or could
be performed. Additionally, there may be a response
shift bias, which indicates that a patient’s values for
health changed over the course of time in the SF-6D,
which is further driven by the SF-12 PCS Score.
Many of the differences between the EQ-5D-3 L,
SF-6D and SGRQ were expected considering differ-
ences in their descriptive system, scoring function,
valuation and range of utility and scoring systems.
Furthermore, poor health states are valued more
highly (in utility terms) in the SF-6D compared to the
EQ-5D-3 L [25, 47, 48]. Additionally, the SF-6D is
generally better able to detect smaller changes in
health compared to the EQ-5D-3 L [48]. There is also
evidence which suggests that the time trade off
method results in greater values for mild or moderate
health states and lower values for severe health states,
which may partly explain our findings [47].
The limitations of this study include having a small
sample of responders which limited some analyses and
decreasing the generalizability of our results. This study
was also disadvantaged as no data regarding HRQoL was
collected at baseline. Instead, patients were assumed to
have an EQ-5D-3 L utility score of -0.402 (representing
an unconscious health state) in the separate trial-based
economic evaluation [49]. Unconsciousness is not a de-
fined health state by the SF-12 or the SGRQ and hence
there were no pre-defined SF-12 or SGRQ QoL or
HRQoL values for the baseline unconscious health state.
In the current EQ-5D-3 L value set, the unconscious
state has been assigned a utility value of -0.402 [49]. This
value suggests that the general public, on average, con-
siders unconsciousness to be “worse than dead (<0)” but
better than being conscious and experiencing problems
on all dimensions (-0.543). Future research must clearly
take into account methodological issues surrounding
measuring and valuing the unconscious health state in
critical care. Issues include whether being unconscious
in this setting represents one health state or a number of
health states, if an individual has any feelings or emo-
tions when unconscious, whether people can value un-
consciousness without knowledge of the preceding and
subsequent health states and whether being asleep is
equivalent to being unconscious for a short time.
Lastly, in order to determine the robustness of the
EQ-5D-3 L and SF-6D utility scores in this population,
advocacy for mapping research is encouraged. Mapping
exercises could be based on using the SGRQ summary
scores from OSCAR or similar trials and mapping onto
the EQ-5D-3 L, EQ-5D-5 L and SF-6D in order to assess
if there is any difference in the original utility scores de-
rived from the OSCAR trial and the estimated utility
scores derived from the mapping exercises.
Conclusion
This study highlights the complications that can arise
when trying to assess the psychometrics of PROMs in
intensive care contexts and hence advocates for re-
searchers and policy makers to notice this gap in evi-
dence and follow through with building evidence
surrounding utility values for the unconscious health
state. In summary, it was considered that generic in-
struments were suitable to measure HRQoL in this
population and showed good properties for most cri-
teria whereas more consideration has to be given to
the role of condition specific instruments in this con-
text. The selection of a preferred PROM for evalu-
ative studies within the ARDS context should
ultimately depend on the relative importance placed
on individual psychometric properties and the import-
ance placed on generation of health utilities for eco-
nomic evaluation purposes.
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Table 9 Correlation between dimensions
EQ5D
Mobility
EQ5D
Self
care
EQ5D
Usual
activity
EQ5D
Pain
EQ5D
Anxiety
depression
SF12
General
health
SF12
Physical
Functioning
SF12 Role
functioning
(Physical)
SF12 Role
functioning
(Emotional)
SF12
Bodily
pain
SF12
Mental
health
SF12
Vitality
SF12 Social
functioning
SGRQ
Symptom
score
SGRQ
Activity
score
SGRQ
Impact
score
SGRQ
Total
score
EQ5D Mobility 1.00
EQ5D SelfCare 0.47 1.00
EQ5D
UsualActivity
0.56 0.40 1.00
EQ5D Pain 0.48 0.60 0.36 1.00
EQ5D Anxiety
Depression
0.23 0.14 0.15 0.33 1.00
SF12 General
Health
−0.57 −0.45 −0.49 −0.53 −0.19 1.00
SF12 Physical
Functioning
−0.63 −0.57 −0.68 −0.62 −0.24 0.64 1.00
SF12 Role
Functioning
(Physical)
−0.51 −0.54 −0.68 −0.62 −0.23 0.63 0.77 1.00
SF12 Role
Functioning
(Emotional)
−0.33 −0.30 −0.32 −0.42 −0.79 0.33 0.36 0.42 1.00
SF12 Bodily
Pain
−0.52 −0.59 −0.32 −0.81 −0.28 0.55 0.65 0.63 0.33 1.00
SF12 Mental
Health
−0.27 −0.16 −0.05 −0.31 −0.80 0.25 0.25 0.21 0.68 0.34 1.00
SF12 Vitality −0.35 −0.24 −0.31 −0.28 −0.32 0.45 0.46 0.37 0.34 0.34 0.45 1.00
SF12 Social
Functioning
−0.31 −0.38 −0.32 −0.43 −0.63 0.39 0.45 0.42 0.68 0.45 0.61 0.36 1.00
SGRQ
Symptom
Score
0.25 0.12 0.29 0.23 0.30 −0.46 −0.42 −0.30 −0.26 −0.28 −0.31 −0.36 −0.33 1.00
SGRQ Activity
Score
0.43 0.24 0.48 0.33 −0.25 −0.48 −0.58 0.44 −0.30 −0.28 −0.22 −0.41 −0.22 0.61 1.00
SGRQ Impact
Score
0.32 0.27 0.45 0.38 0.33 −0.45 −0.59 −0.46 −0.36 −0.29 −0.30 −0.45 −0.32 0.69 0.85 1.00
SGRQ Total
Score
0.38 0.26 0.45 0.36 0.30 −0.49 −0.59 −0.44 −0.33 −0.30 −0.28 −0.45 −0.29 0.77 0.94 0.96 1.00
Values in bold did not correlate at 95 % confidence
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SG: standard gamble; SGRQ: St Georges respiratory questionnaire; TTO: time
trade off method; VAS: visual analogue scale.
Competing interest
The authors declare no conflict of interest.
Authors’ contributions
Study conception and design: SP & MD designed and conceptualised the
study. Analysis and interpretation of data: HS, MD, JP, SP conducted the
analysis and interpretation. Drafting of manuscript: HS, MD, JP & SP drafted
the manuscript. Critical revision: HS, MD, JP & SP conducted the critical
revision. All authors read and approved the final manuscript.
Acknowledgements
The OSCAR study was funded by the National Institute for Health Research
Technology Assessment Programme (project number 06/04/01). The authors
thank Prof Duncan Young, Prof Claire Hulme and the OSCAR trial team for
permission to use the OSCAR trial data.
This study is based on an MSc Thesis conducted by Hiral Anil Shah and
supervised by Melina Dritsaki, Joshua Pink and Stavros Petrou.
Author details
1Public Health Foundation of India, Delhi NCR, India. 2Warwick Clinical Trials
Unit, Division of Health Sciences, Warwick Medical School, University of
Warwick, Coventry CV4 7AL, UK. 3Oxford Clinical Trials Research Unit, Nuffield
Department of Orthopeadics, Rheumatology and Musculosceletal Sciences,
University of Oxford, Oxford OX3 7HE, UK.
Received: 21 April 2015 Accepted: 21 January 2016
References
1. Arroliga AC, Ghamra ZW, Perez Trepichio A, Perez Trepichio P, Komara Jr JJ,
Smith A, et al. Incidence of ARDS in an adult population of northeast Ohio.
Chest. 2002;121(6):1972–6.
2. Bersten AD, Edibam C, Hunt T, Moran J. Australian, New Zealand Intensive
Care Society Clinical Trials G. Incidence and mortality of acute lung injury
and the acute respiratory distress syndrome in three Australian States. Am J
Respir Crit Care Med. 2002;165(4):443–8.
3. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, et
al. Epidemiology and outcome of acute lung injury in European intensive
care units. Results from the ALIVE study. Intensive Care Med. 2004;30(1):51–61.
4. Goss CH, Brower RG, Hudson LD, Rubenfeld GD, Network ARDS. Incidence
of acute lung injury in the United States. Crit Care Med. 2003;31(6):1607–11.
5. Hughes M, Grant IS, MacKirdy FN. Incidence and mortality after acute
respiratory failure and acute respiratory distress syndrome in Sweden,
Denmark, and Iceland. Am J Respir Crit Care Med. 2000;162(1):332–3.
6. Hughes M, MacKirdy FN, Ross J, Norrie J, Grant IS, Scottish Intensive Care
Society. Acute respiratory distress syndrome: an audit of incidence and
outcome in Scottish intensive care units. Anaesthesia. 2003;58(9):838–45.
7. MacCallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit
Care. 2005;11(1):43–9.
8. Roca O, Sacanell J, Laborda C, Perez M, Sabater J, Burgueno MJ, et al.
Cohort study on incidence of ARDS in patients admitted to the ICU and
prognostic factors of mortality. Med Intensiva. 2006;30(1):6–12.
9. Sigvaldason K, Thornormar K, Bergmann JB, Reynisson K, Magnusdottir H,
Stefansson TS, et al. The incidence and mortality of ARDS in Icelandic
intensive care units 1988-1997. Laeknabladid. 2006;92(3):201–7.
10. Bellingan DG. Promising new treatment for respiratory syndrome University
College London HospitalsJanuary 2014 [08/07/2014]. Available from:
http://www.uclh.nhs.uk/News/Pages/Promisingnewtreatmentforlife-
threateningrespiratorysyndrome.aspx.
11. Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, et al. The
effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression
and on acute respiratory distress syndrome mortality: an open-label study.
Lancet Respir Med. 2014;2(2):98–107.
12. Dushianthan A, Grocott MP, Postle AD, Cusack R. Acute respiratory distress
syndrome and acute lung injury. Postgrad Med J. 2011;87(1031):612–22.
13. Perkins GD, Gates S, Lamb SE, McCabe C, Young D, Gao F. Beta Agonist
Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind,
placebo-controlled of intravenous infusion of salbutamol in the acute
respiratory distress syndrome. Trials. 2011;12:113.
14. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung
injury. Chest. 2007;131(2):554–62.
15. Dawson J, Doll H, Fitzpatrick R, Jenkinson C, Carr AJ. The routine use of patient
reported outcome measures in healthcare settings. BMJ. 2010;340:c186.
16. Browne J, Jamieson L, Lewseyet J, van der Meulen J, Black N, Cairnsal J,
et al. Patient Reported Outcome Measures (PROMs) in Elective Surgery -
Report to the Department of Health. London School of Hygiene & Tropical
Medicine, 2007. https://www.lshtm.ac.uk/php/
departmentofhealthservicesresearchandpolicy/assets/proms_report_12_dec_
07.pdf. Accessed date 7 Aug 2014.
17. McKenna SP. Measuring patient-reported outcomes: moving beyond
misplaced common sense to hard science. BMC Med. 2011;9:86.
18. Menn P, Weber N, Holle R. Health-related quality of life in patients with
severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and
SGRQ. Health Qual Life Outcomes. 2010;8:39.
19. Jutte JE, Needham DM, Pfoh ER, Bienvenu OJ. Psychometric evaluation of
the hospital anxiety and depression scale 3 months after acute lung injury. J
Crit Care. 2015;30(4):793–8.
20. Galvagno Jr SM. Assessing health-related quality of life with the EQ-5D: Is this
the best instrument to assess trauma outcomes? Air Med J. 2011;30(5):258–63.
21. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties
of the St George’s Respiratory Questionnaire (SGRQ) in patients with
idiopathic pulmonary fibrosis: a literature review. Health Qual Life
Outcomes. 2014;12:124.
22. Young DLS, Shah S, MacKenzie I, Tunnicliffe W, Lall R, Rowan K, et al. High-
frequency oscillation for acute respiratory distress syndrome. N Engl J Med.
2013;28(368):795–805.
23. Health Technology Assessment Programme. OSCAR full protocol
Southampton [22/01/2015]. Available from: http://www.nets.nihr.ac.uk/__
data/assets/pdf_file/0020/51275/PRO-06-04-01.pdf. .
24. Lall RHP, Young D, Hulme C, Hall P, Shah S, MacKenzie I, et al. A randomised
controlled trial and cost-effectiveness analysis of high-frequency oscillatory
ventilation against conventional artificial ventilation for adults with acute
respiratory distress syndrome.The OSCAR (OSCillation in ARDS) study. Health
Technol Assess. 2015;19(23):1–177.
25. Pink J, Petrou S, Williamson E, Williams M, Lamb SE. Properties of patient-
reported outcome measures in individuals following acute whiplash injury.
Health Qual Life Outcomes. 2014;12:38.
26. Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Validation and comparison
of EuroQol and short form 6D in chronic prostatitis patients. Value Health.
2010;13(5):649–56.
27. Dolan P GC, Kind P, Williams A. A social tariff for EuroQol: results from a UK
general population survey. Centre for Health Economics: University of York,
1995. Available from: http://ideas.repec.org/p/chy/respap/138chedp.html.
Accessed date 25 jan 2016.
28. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al.
Cross-validation of item selection and scoring for the SF-12 Health Survey in
nine countries: results from the IQOLA Project. International Quality of Life
Assessment. J Clin Epidemiol. 1998;51(11):1171–8.
29. Ware Jr J, Kosinski M, Keller SD. A 12-item short-form health survey:
construction of scales and preliminary tests of reliability and validity. Med
Care. 1996;34(3):220–33.
30. Sheffield Uo. SF-6D: A brief overview 2014 [30/06/2014]. Available from:
https://www.sheffield.ac.uk/scharr/sections/heds/mvh/sf-6d.
31. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure
of health status for chronic airflow limitation. The St. George’s Respiratory
Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–7.
32. Mokkink LBTC, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, et al.
International consensus on taxonomy, terminology, and definitions of
Shah et al. Health and Quality of Life Outcomes  (2016) 14:15 Page 12 of 13
measurement properties for health-related patient-reported ouctomes:
results of the COSMIN study. J Clin Epidemiol. 2010;63:737–45.
33. Brazier J, Deverill M. A checklist for judging preference-based measures of
health related quality of life: learning from psychometrics. Health Econ.
1999;8(1):41–51.
34. Turner N, Campbell J, Peters T, Wiles N, Hollinghurst S. A comparison of four
different approaches to measuring health utility in depressed patients.
Health Qual Life Outcomes. 2013;11(1):81.
35. The ADTF. Acute respiratory distress syndrome: The berlin definition. JAMA.
2012;307(23):2526–33.
36. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classification system. Crit Care Med. 1985;13(10):818–29.
37. Richard S. Irwin MD (Editor) JMRME. Irwin and Rippe’s Intensive Care
Medicine. 7TH ed. Philadelphia: LWW; 2011.
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2 ed:
Hillsdale, N.J: L. Erlbaum Associates, Routledge; 1988.
39. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-
5D and SF-6D based on hypothetical preferences in a general population.
Health Econ. 2005;14(11):1169–89.
40. Sherpa CT, LeClerq SL, Singh S, Naithani N, Pangeni R, Karki A, et al.
Validation of the St. George’s Respiratory Questionnaire in Nepal. Chronic
Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2015;2(4):
281-289.
41. Burton M, Walters SJ, Saleh M, Brazier JE. An evaluation of patient-reported
outcome measures in lower limb reconstruction surgery. Qual Life Res.
2012;21(10):1731–43.
42. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing
responsiveness: a critical review and recommendations. J Clin Epidemiol.
2000;53(5):459–68.
43. Jum C. Nunnally IHB. Psychometric Theory. 3rd ed. New York: McGraw-Hill;
1994.
44. Rubin A. Statistics for evidence-based practice and evaluation. Belmont, CA:
Cengage Learning; 2012.
45. Streiner DL. Starting at the beginning: an introduction to coefficient alpha
and internal consistency. J Pers Assess. 2003;80(1):99–103.
46. Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-
5D three-level system with a five-level version. Value Health. 2008;11(2):275–84.
47. Tsuchiya A, Brazier J, Roberts J. Comparison of valuation methods used to
generate the EQ-5D and the SF-6D value sets. J Health Econ. 2006;25(2):
334–46.
48. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D
and SF-6D across seven patient groups. Health Econ. 2004;13(9):873–84.
49. Kind P. UK Population Norms for the EQ-5D. University of York: Centre for
Health Economics, 1999. http://www.york.ac.uk/che/pdf/DP172.pdf.
Accessed date 25 jan 2016.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shah et al. Health and Quality of Life Outcomes  (2016) 14:15 Page 13 of 13
